On March 01, Karyopharm Therapeutics Inc. (KPTI) provided U.S. regulatory updates on Selinexor in advanced or recurrent endometrial cancer. Consequently, the stock suffered a huge
Karyopharm Therapeutics Inc. (KPTI) is a commercial-stage biotherapeutics company engaged in developing cancer therapies. The company’s pioneer Selective Inhibitor of Nuclear Export compound technology was
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.